NCT05486208

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

A Phase 1, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of LY3844583 in Healthy Participants, and Multiple-Dose Study of LY3844583 in Healthy Participants and Patients With Atopic Dermatitis

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 102 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3844583 in healthy participants and participants with atopic dermatitis. The study will also assess how fast LY3844583 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants and participants with atopic dermatitis. The study will be conducted in three parts and each participant will enroll in one part. The study will last up to 88, 116, and 186 days with 10, 13, and 14 visits for each participant in parts A, B, and C, respectively.

Conditions

• Healthy
• Dermatitis, Atopic

Interventions

Type	Name	Description
DRUG	LY3844583	Administered SC and/or IV.
DRUG	Placebo	Administered SC and/or IV.

Timeline

• Start date: 2022-08-11
• Primary completion: 2024-01-20
• Completion: 2024-01-20
• First posted: 2022-08-03
• Last updated: 2024-05-10

Locations

3 sites across 2 countries: United States, Japan

Regulatory

• FDA-regulated drug study